Axogen Completes Acquisition of BioCircuit Technologies
Axogen announced the closing of the acquisition, which contributes $6M to Q4 2026 and $34M to 2027 revenue, marking a strategic expansion of sutureless nerve repair capabilities.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed